BPC-157: Body Protection Compound Research Overview

Overview

Body Protection Compound-157 (BPC-157) is a synthetic 15-amino-acid pentadecapeptide derived from a cytoprotective segment isolated from human gastric juice. It was first isolated and synthesised by Sikiric and colleagues at the University of Zagreb in the early 1990s.

In preclinical research it has been studied for cytoprotective, regenerative and anti-inflammatory effects, with particular interest in angiogenesis, tendon and ligament healing, and gastrointestinal mucosal protection. Unlike many peptides, it demonstrates stability in acidic gastric environments.

BPC-157 is strictly investigational and is not approved by any global regulator for human use, including the Australian TGA. In Australia it is listed in Schedule 4 (Prescription Only Medicine) of the Poisons Standard, and it is classified under the WADA Prohibited List (banned at all times for competing athletes). Silverback Peptides supplies it for laboratory research only.

Mechanism of Action

BPC-157 does not act on a single identified membrane receptor. Research literature instead describes it as an indirect modulator of several tissue-repair and cytoprotective signalling cascades:

• VEGFR2 activation — upregulates VEGF expression and activates VEGFR2, driving the downstream Akt-eNOS pathway, endothelial migration and angiogenesis.
• FAK-paxillin cascade — in tendon and ligament fibroblasts, activates focal adhesion kinase (FAK)-paxillin signalling, central to cell adhesion and migration to injury sites.
• Growth hormone receptor upregulation — in vitro models show increased GHR gene and protein expression, enhancing fibroblast proliferative response.
• Cytokine and nitric-oxide modulation — reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and modulates the nitric-oxide system.

State of the Evidence

It is important to distinguish the breadth of preclinical research from the near-absence of human data. In animal models, systemic or oral BPC-157 has been reported to promote mucosal healing, protect against NSAID-induced gastric ulcers, and accelerate healing of transected Achilles tendons and muscle injuries, improving biomechanical and collagen-organisation parameters.

However, there are no published randomised, double-blind, placebo-controlled human trials establishing safety or efficacy. The registered trial NCT02637284 was terminated without published results. The only human literature is a small retrospective review of 12 patients given intra-articular knee injections; it was open-label, uncontrolled and retrospective, and does not constitute valid evidence of safety or efficacy.

Storage & Handling

Lyophilised BPC-157 powder should be stored sealed at −20°C for long-term stability. After reconstitution with bacteriostatic water or sterile saline, store at 2–8°C, protected from light.

Because the peptide lacks a complex tertiary fold it is relatively stable, but repeated freeze-thaw cycles of reconstituted solution should still be avoided.